Business Standard

Monday, December 23, 2024 | 03:56 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Cipla open to forge a partnership to distribute Covid-19 vaccines in India

The company already makes and markets antiviral drugs like remdesivir, favipiravir in India apart from importing and distributing Roche's tocilizumab (Actemra)

Cipla, Cipla logo, Cipla headquarters
Premium

An employee works at the reception area of Cipla at its headquarters in Mumbai. Photo: Reuters

Sohini Das Mumbai
Cipla, which has a strong portfolio of Covid-19 drugs, says it is now open to forge a partnership to distribute Covid vaccines in India.

“We are open to having a vaccine partnership. A company that will be able to do vaccine distribution successfully in India will have significant distribution muscle – like large warehouses, cold chain capabilities, footprint throughout India. We fit the bill well. We are open to it, but as of now nothing to report,” said Kedar Upadhye, global CFO of Cipla. Cipla does not want to get into vaccine manufacturing. It is augmenting its Covid-19 therapy portfolio too.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in